Sanofi
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
September 26, 2025Research and Development Dupixent, Regeneron, Sanofi, urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
August 14, 2025Medical Communications, Research and Development European Alliance of Associations for Rheumatology, European Medicines Agency, IgG4-related disease, Rheumatology, Sanofi
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, for the treatment …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
August 6, 2025Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …
FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate
August 6, 2025Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma
The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …
Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment
July 30, 2025Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma
Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …
FDA grants orphan drug designation to antibody-mediated rejection treatment
June 26, 2025Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation
Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …
Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
June 24, 2025Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …
Dupixent improves symptoms in patients with skin of colour, study shows
June 11, 2025Advocacy Development, Medical Education, Research and Development Dermatology, Dupixent, Regeneron, Sanofi, atopic dermatitis, dermatology, underserved populations
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at the Revolutionizing Atopic Dermatitis Conference, …
Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases
June 3, 2025Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases
Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …
Teen band 1Type releases single to raise awareness of type 1 diabetes
May 30, 2025Medical Communications, Medical Education 1Type, Diabetes, Rise Up, Sanofi, Stagecoach Performing Art, autoimmune type 1 diabetes
Four teenagers living with autoimmune type 1 diabetes (aT1D) have released a single aimed at raising awareness of the condition …
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline
May 23, 2025Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases
Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …
Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant
May 6, 2025Mergers and Acquisitions (OTC & VMS), Clayton, Clayton Dubilier & Rice (CD&R), Corporate, M&A, Opella, Sanofi, agreement
Sanofi and Clayton, Dubilier & Rice (CD&R) have officially closed the sale of a controlling 50% stake in Opella, Sanofi’s …
Sobi and Sanofi’s Foundation S renew partnership with World Federation of Hemophilia
April 28, 2025Pharmacy sales & educational programmes, Sales and Marketing Haematology, Sanofi, World Federation of Hemophilia, bleeding disorder, sobi
Sobi and Sanofi, through its organisation Foundation S, have extended their partnership with the World Federation of Hemophilia (WFH) Humanitarian …
Dupixent approved as first biologic medicine in Japan for COPD patients
April 2, 2025Research and Development COPD, Chronic Diseases, Regeneron, Sanofi, biotech, respiratory disease
The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment …
Qfitlia approved by FDA to treat haemophilia A or B
March 31, 2025Research and Development FDA, Haematology, Sanofi, haemophilia, pharma
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran) as the first therapy in the US to treat …
